NEUROBO PHARMACEUTICALS INC (NRBO) Stock Price, Forecast & Analysis
USA - NASDAQ:NRBO - US64132R4048 - Common Stock
NRBO Key Statistics, Chart & Performance
The current stock price of NRBO is 2.36 USD. In the past month the price decreased by -10.94%. In the past year, price decreased by -34.43%.
NRBO Latest News, Press Relases and Analysis
NRBO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.76 | 413.38B | ||
| AMGN | AMGEN INC | 15.62 | 183.96B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25 | 111.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 74.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.02 | 60.37B | ||
| INSM | INSMED INC | N/A | 41.72B | ||
| NTRA | NATERA INC | N/A | 28.28B | ||
| BIIB | BIOGEN INC | 9.84 | 24.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.88 | 21.34B | ||
| INCY | INCYTE CORP | 16.23 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.34 | 14.24B |
Related stock screener links
About NRBO
Company Profile
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.
Company Info
NEUROBO PHARMACEUTICALS INC
545 Concord Avenue, Suite 210
Cambridge MASSACHUSETTS 02116 US
CEO: Richard Kang
Employees: 8
Phone: 18577029600
NEUROBO PHARMACEUTICALS INC / NRBO FAQ
Can you describe the business of NEUROBO PHARMACEUTICALS INC?
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.
What is the current price of NRBO stock?
The current stock price of NRBO is 2.36 USD. The price increased by 0.43% in the last trading session.
Does NEUROBO PHARMACEUTICALS INC pay dividends?
NRBO does not pay a dividend.
What is the ChartMill technical and fundamental rating of NRBO stock?
NRBO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for NEUROBO PHARMACEUTICALS INC?
NEUROBO PHARMACEUTICALS INC (NRBO) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of NRBO stock?
NEUROBO PHARMACEUTICALS INC (NRBO) has a market capitalization of 20.34M USD. This makes NRBO a Nano Cap stock.
NRBO Technical Analysis
NRBO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NRBO. The financial health of NRBO is average, but there are quite some concerns on its profitability.
NRBO Financial Highlights
Over the last trailing twelve months NRBO reported a non-GAAP Earnings per Share(EPS) of -6. The EPS increased by 62.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.23% | ||
| ROE | -214.1% | ||
| Debt/Equity | 0 |
NRBO Forecast & Estimates
8 analysts have analysed NRBO and the average price target is 27.2 USD. This implies a price increase of 1052.54% is expected in the next year compared to the current price of 2.36.